Novo Nordisk CFO Karsten Munk Knudsen speaks on Bloomberg Television about earnings, tariffs and the impact of compounding in ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth ...

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions ...

Novo Nordisk CFO Karsten Munk Knudsen speaks on Bloomberg Television ... compounding "significantly more" than its competitor Eli Lilly. All 3 of Trump's Supreme Court appointees just voted ...

Multinational pharmaceutical firms have been queuing up to announce multi-billion-dollar investments in US facilities. Roche, ...

CFO Karsten Munk Knudsen said he expects Wegovy sales ... which was short of the projected 25% weight reduction. Eli Lilly released trial results for its latest weight-loss drug, retatrutide ...

Karsten Munk Knudsen Thank you ... cash patients may prefer Lilly given a cheaper syringe vial strategy and [indiscernible] perception and efficacy safety is beginning to edge with Wegovy.

Novo Nordisk Chief Financial Officer Karsten Munk Knudsen said in an interview it takes years ... His comments follow announcements by pharma companies including Novartis, Eli Lilly and Roche of huge ...

Eli Lilly, New Amsterdam, Boehringer-Ingelheim, Cytokinetics, Nodthera, Tourmaline Bio and Cardio Therapeutics; has minority shareholder equity positions in Uppton, Bitteroot Bio, and Angiowave ...

Danish pharma manufacturer Novo Nordisk’s chief financial officer, Karsten Munk Knudsen, expressed doubts on 7 May about ... United Kingdom), Eli Lilly (based in Indianapolis, Indiana), and Roche ...